Fusion Antibodies (LON:FAB) Stock Price Down 38.5% – What’s Next?

Fusion Antibodies plc (LON:FAB)’s stock price fell 38.5% during trading on Thursday. The company traded as low as GBX 4.70 and last traded at GBX 6. 7,380,445 shares changed hands during trading, an increase of 1,568% from the average daily volume of 442,459 shares. The stock had previously closed at GBX 9.75.

Fusion Antibodies Trading Down 38.5%

The company has a quick ratio of 2.36, a current ratio of 2.82 and a debt-to-equity ratio of 20.41. The company has a market cap of £7.51 million, a P/E ratio of -6.00 and a beta of 1.24. The firm’s 50 day moving average is GBX 10.99 and its two-hundred day moving average is GBX 11.86.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. As a group, equities research analysts anticipate that Fusion Antibodies plc will post -130.00 EPS for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.